Comparison of the efficacy and safety of third-line treatments for advanced gastric cancer: A systematic review and network meta-analysis

BACKGROUND: Many options for third-line treatment of advanced gastric cancer (GC) or gastroesophageal junction carcinoma (GEJC) have been developed. Therapies including immunotherapy (nivolumab), chemotherapy (irinotecan, FTD/TPI), targeted therapy (apatinib), and antibody drug conjugates (ADC) have...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Chan, Xiang, Yaoxian, Wang, Jing, Yan, Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10016689/
https://www.ncbi.nlm.nih.gov/pubmed/36937403
http://dx.doi.org/10.3389/fonc.2023.1118820

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10016689/
https://www.ncbi.nlm.nih.gov/pubmed/36937403
http://dx.doi.org/10.3389/fonc.2023.1118820

Ejemplares similares